APA (7th ed.) Citation

Banerji, U. (2018). A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers. The American Association for Cancer Research (AACR).

Chicago Style (17th ed.) Citation

Banerji, U. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers. The American Association for Cancer Research (AACR), 2018.

MLA (9th ed.) Citation

Banerji, U. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers. The American Association for Cancer Research (AACR), 2018.